Musculoskeletal Disorder, Pain Management
Conditions
Keywords
Musculoskeletal Disorder, Nuberol Forte, Pakistan
Brief summary
The global prevalence of Musculoskeletal disorders (MSD) ranges from 14% to as high as 42%. In addition WHO also estimates that 40% of people over the age of 60 years suffer from MSD and about 80% of the people have had low back pain at some point in their life. In Pakistan, to estimate the prevalence of MSD, there is no data available based on the local population. Locally, studies were conducted on the specific subject pools mainly considering the work related musculoskeletal disorders and backache. However, no real data is available for the symptomatic management of painful musculoskeletal disorders in multiple settings to calculate more generalizable results. So this study is planned and if we found good results then it will help physicians to prescribe the above said medicine to all such cases.
Detailed description
The management of musculoskeletal pain is complex therefore plethora of treatment options are available include non-pharmacological treatments , complementary therapies, and pharmacological interventions. In order to provide optimal care to patients with musculoskeletal pain and ensure the efficient use of healthcare resources, a comprehensive overview of the available evidence for the most effective treatment options for musculoskeletal pain presentations is essential. In this context, an observational study is planned on the efficacy and safety of analgesic combination (i.e Nuberol Forte®). Nuberol Forte® is a combination of muscle relaxant (Orphanedrine) and an analgesic/antipyretic (Paracetamol/Acetaminophen). There are clear indications that the combination of Orphenadrine with Paracetamol may give increased antinociceptive activity and duration of action over and above the use of Orphenadrine or Paracetamol alone.
Interventions
DRUGCombination of Paracetamol 650mg + Orphenadrine 50mg
In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
Sponsors
The Searle Company Limited Pakistan
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patient with a clinical history of painful musculoskeletal disorder from last 1 year * Patient aged ≥18 and ≤70 years inclusive of either sex * Patient with ability to understand and sign written informed consent form.
Exclusion criteria
* Known hypersensitivity to Nuberol Forte product, the metabolites, or formulation excipients. * Patients with Glaucoma, prostatic hypertrophy or obstruction at the bladder neck, myasthenia gravis, oesophageal spasm and pyloric or duodenal obstruction. * Treated with Nuberol Forte to evaluate safety as per approved prescribing information for Nuberol Forte in Pakistan. * Pregnant (assesed on LMP) or breast feeding women (assessed on interview).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the effectiveness of Nuberol Forte from baseline to 2 weeks | 2 weeks | the pain, muscle spasm and stiffness are assessed by Muscle & Joint Measure scale. |
| To assess the safety of Nuberol Forte in the cases presenting with Musculoskeletal disorder | 2 weeks | Safety is monitored from the first dose of the study drug |
Countries
Pakistan
Outcome results
None listed